EDRH
TOVX icon

Edmond de Rothschild Holding’s Theriva Biologics TOVX Stock Holding History

Edmond de Rothschild Holding’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-42
Closed -$345K – 839
2017
Q3 		$345K Hold
42
– – 0.01% 416
2017
Q2 		$209K Hold
42
– – 0.01% 474
2017
Q1 		$233K Hold
42
– – 0.01% 467
2016
Q4 		$282K Buy
42
+9
+27% +$92.4K 0.01% 451
2016
Q3 		$499K Buy
33
+1
+3% +$15K 0.02% 376
2016
Q2 		$504K Buy
32
+6
+23% +$113K 0.02% 365
2016
Q1 		$543K Buy
26
+9
+53% +$135K 0.02% 347
2015
Q4 		$344K Hold
17
– – 0.01% 418
2015
Q3 		$340K Buy
+17
New +$418K 0.01% 390

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Edmond de Rothschild Holding's TOVX Position: Q4 2017 in Review

Edmond de Rothschild Holding sold out of Theriva Biologics (TOVX) in Q4 2017, closing a stake of 42 shares — an estimated $345K sold.

Edmond de Rothschild Holding first reported a position in TOVX in Q3 2015 and held it in 9 quarters. The position peaked at $543K in Q1 2016. 48 funds tracked by Wall St. Rank hold TOVX as of Q4 2017.

  • Edmond de Rothschild Holding reported no remaining Theriva Biologics position as of Q4 2017 after selling out during the quarter.
  • Edmond de Rothschild Holding sold 42 Theriva Biologics shares in Q4 2017, an estimated $345K.
  • Edmond de Rothschild Holding first reported a position in Theriva Biologics in Q3 2015 and held it in 9 quarters.
  • Edmond de Rothschild Holding's Theriva Biologics position peaked at $543K in Q1 2016.
  • 48 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2017.

Based on Edmond de Rothschild Holding's 13F filing for Q4 2017, filed 14 Feb 2018.